Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glucosamine/chondroitin

This article was originally published in The Tan Sheet

Executive Summary

Osteoarthritis health claim would be possible based on positive results from, and subsequent NIH "authoritative statement" on, University of Utah study, Hyman, Phelps & McNamara (D.C.) partner Stephen McNamara maintains at Nutracon 2001 in San Diego July 9. Study, co-sponsored by NCCAM, is slated for completion in 2003 (1"The Tan Sheet" April 2, In Brief). ODS Director Paul Coates, PhD, calls health claim "an interesting possibility," but notes negative could lead to "authoritative statement" against ingredients

You may also be interested in...



NCCAM

Results from glucosamine/chondroitin trial in treating osteoarthritis (co-sponsored by National Institute of Arthritis & Musculoskeletal & Skin Diseases) will be available in roughly two years, NCCAM Director Stephen Straus, MD, tells House Appropriations/labor-HHS subcommittee at hearing March 28. No adverse events have been reported to date, he says. In addition, studies on effects of soy for menopause and Chinese herbal combination PC-SPES for prostate cancer are progressing and center's new PubMed database for CAM information is being visited at a promising rate, Straus notes. Subcommittee hearing was first to address NCCAM funding under new Chair Ralph Regula (R-Ohio), who replaced six-year former Chair John Porter (R-Ill.) following his retirement

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel